BioTuesdays

Tag - INMB

INmune Bio

HCW starts INmune Bio at buy; PT $11.50

H.C. Wainwright launched coverage of INmune Bio with a “buy” rating and price target of $11.50. The stock closed at $5.94 on Aug. 20. INmune Bio is an immunology company developing therapies targeting innate immunity to...

INmune Bio

Maxim starts INmune Bio at buy; PT $13

Maxim Group launched coverage of INmune Bio (NASDAQ:INMB) with a “buy” rating and $13 price target. The stock closed at $7.73 on March 18. INmune Bio is a clinical-stage immunotherapy company with three drug programs...

Subscribe

Sign up to our weekly BioTuesdays newsletter.